Companies: 10,795·Total market cap: $144.5T
Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc.

PHATNASDAQHealthcare● Active
$9.93
$-0.20(-1.96%)
Market Cap$792055843
P/E Ratio
52W High$18.31
52W Low$4.471
Overview

Phathom Pharmaceuticals, Inc. (PHAT) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

phat · stock forecast · 9 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 9 Wall Street analysts in the past 3 months

SellBuy

Buy

9 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
8
Hold
1
Sell
0
Strong Sell
0
Total: 9 · Buy rate: 88.9%

12-Month Price Target

High

$28.00

Consensus

$24.67

+151.9% upside

Low

$18.00

Median: $28 · Last Close: $9.79

The Phathom Pharmaceuticals, Inc. (PHAT) analyst consensus is Buy, based on ratings from 9 Wall Street analysts over the past 3 months. The average 12-month PHAT price target is $24.67, representing +151.9% upside from the current price of $9.79.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $25 (151.9%)

Consensus Target

$24.67

151.9% upside

High Target

$28

185.9%

Low Target

$18

83.8%

Current Price

$9.79

as of today

Based on analyst price targets, the PHAT stock price prediction for the next 12 months ranges from $18 to $28. The consensus PHAT price forecast of $24.67 implies 151.9% upside from the current price of $9.79.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$9.315.00%

1-day model range: $9.24–$9.37. Peak: $9.37 (-5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$13+30.2%
2028$15+51.8%
2029$16+65.7%
2030$17+74.0%
2031+78.9%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

0%7%93%
0Buy
1Neutral
13Sell
RSI (14)33.4Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · PHAT · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$9.91SELL
MA 10$10.05SELL
MA 20$11.02SELL
MA 50$11.62SELL
MA 100$11.93SELL
MA 200$12.83SELL
Current $PHAT · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$9.93SELL
EMA 10$10.19SELL
EMA 20$10.71SELL
EMA 50$11.38SELL
EMA 100$11.87SELL
EMA 200$11.95SELL
Current $PHAT · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Barclays2026-03-27
Upgrade ↑
Equal WeightOverweight
Guggenheim2026-02-27
Maintains
BuyBuy
HC Wainwright & Co.2025-10-31
Maintains
BuyBuy
HC Wainwright & Co.2025-06-09
Maintains
BuyBuy
Craig-Hallum2025-06-09
Maintains
BuyBuy
Needham2025-06-06
Maintains
BuyBuy
HC Wainwright & Co.2025-05-02
Maintains
BuyBuy
Goldman Sachs2025-05-02
Maintains
NeutralNeutral
Guggenheim2025-05-02
Maintains
BuyBuy
Craig-Hallum2025-05-02
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Phathom Pharmaceuticals, Inc. (PHAT) stock. Of the recent 91 rating actions, 3 were upgrades and 2 were downgrades. 9 analysts currently cover PHAT.

Analyst Recommendation Trends

Buy ratings413
Hold ratings101
Sell ratings00

PHAT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$334M

↓ 55.8% YoY

Revenue Next Year

$540M

↑ 61.6% YoY

EPS This Year

$-0.62

EPS Next Year

$1.19

↓ 291.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast PHAT EPS of $-0.62 for the current fiscal year, based on estimates from 3 analysts. The PHAT revenue forecast is $334M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The PHAT stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PHAT price target is $24.67 (+151.9% upside), with an analyst consensus of Buy.

The PHAT short-term stock prediction for tomorrow is $9.31 (-5.00%). The PHAT stock price prediction for 2027 estimates an average of $13. The PHAT stock prediction for 2030 projects a range of $16–$18.

Phathom Pharmaceuticals, Inc. trades on NASDAQ under the ticker PHAT. The PHAT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 89% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

PHAT forecast · 8 questions

According to 9 Wall Street analysts, the average 12-month PHAT price target is $24.67, with a high forecast of $28.00 and a low of $18.00. The median price target is shown in the chart above when available. This implies +151.9% potential upside from the current price of $9.79.

PHAT price targetWhat is PHAT price targetPHAT analyst price targetPHAT 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.